3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
16
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Taxes
8
Folfox protocol
8
Drug Therapy
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
tremelimumab
6
Endoscopy, Digestive System
6
Endoscopy
6
Biopsy
6
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma Of Esophagus
×
zimberelimab
×
Clear all
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled
NCT05568095
2026-06-02
STAR-221
Arcus Biosciences, Inc.
Phase 3
Active not recruiting
1,040 enrolled